Human Phospho-VEGFR2/KDR DuoSet IC ELISA, 2 Plate

Human umbilical vein endothelial cells (HUVEC) were treated with 100 ng/mL recombinant human VEGF165 (Catalog # 293-VE) for five minutes to induce tyrosine phosphorylation of VEGF R2. Dilutions of HUVEC lysates were analyzed by this ELISA (Catalog # DYC1766) and IP-Western blot (inset). IPs were performed using an anti-VEGF R2 monoclonal antibody and anti-mouse IgG agarose. Immunoblots were incubated with a biotinylated anti-phospho-tyrosine monoclonal antibody (Catalog # BAM1676) to detect phospho-VEGF R2 (p-VEGF R2). Bands were visualized with Streptavidin-HRP (Catalog # DY998) followed by chemiluminescent detection. Blots were stripped and total VEGF R2 (VEGF R2) was detected using a biotinylated polyclonal anti-VEGF R2 antibody (Catalog # BAF357).

HUVECs were untreated or treated with 100 ng/mL recombinant human VEGF165 for five minutes. ELISA and IP-Western blot (inset) analyses were performed using 100 μg and 1000 μg of lysate, respectively. IP-Western blots were performed as described in Figure 1.

HUVECs were treated with 100 ng/mL of human recombinant VEGF165 for five minutes. The indicated amounts of extracellular domains of recombinant VEGF R2 (Catalog # 357-KD), VEGF R1 (Catalog # 321-FL) or VEGF R3 (Catalog # 349-F4) were added to 100 μg lysate and analyzed by this ELISA. Competition was observed only with recombinant VEGF R2.

• Reactivity: Hu
• Applications: ELISA
• Conjugate: Biotin

Human Phospho-VEGFR2/KDR DuoSet IC ELISA, 2 Plate Summary

• Source: N/A
• Assay Type: Solid Phase Sandwich ELISA
• Inter-Assay: See PDF Datasheet for details
• Intra-Assay: See PDF Datasheet for details
• Spike Recovery: See PDF Datasheet for details
• Sample Volume: See PDF Datasheet for details
• Gene: KDR

Applications/Dilutions

• Dilutions:
  • ELISA
• Application Notes: No significant interference observed with available related molecules.

Packaging, Storage & Formulations

• Storage: Store the unopened product at 2 - 8 °C. Do not use past expiration date.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Human Phospho-VEGFR2/KDR DuoSet IC ELISA, 2 Plate

• CD309 antigen
• CD309
• EC 2.7.10
• EC 2.7.10.1
• Fetal liver kinase 1
• fetal liver kinase-1
• Flk1
• Flk-1
• FLK1tyrosine kinase growth factor receptor
• KDR
• kinase insert domain receptor (a type III receptor tyrosine kinase)
• Kinase insert domain receptor
• KRD1
• Ly73
• Protein-tyrosine kinase receptor flk-1
• soluble VEGFR2
• vascular endothelial growth factor receptor 2
• VEGF R2
• VEGFR
• VEGFR2
• VEGFR-2

Background

VEGF R1 (Flt-1), VEGF R2 (KDR/Flk-1), and VEGF R3 (Flt-4) belong to the class III subfamily of receptor tyrosine kinases (RTKs). All three receptors contain seven immunoglobulin-like repeats in their extracellular domain and kinase insert domains in their intracellular region. They are best known for regulating VEGF family-mediated vasculogenesis, angiogenesis, and lymphangiogenesis. They are also mediators of neurotrophic activity and regulators of hematopoietic development. VEGF R2 is thought to be the primary inducer of VEGF-mediated blood vessel growth, while VEGF R3 plays a significant role in VEGF-C and VEGF-D-mediated lymphangiogenesis.

Publications for VEGFR2/KDR/Flk-1 (DYC1766-2)(13)

Publications using DYC1766-2

• Erning, K;Wilson, KL;Smith, CS;Nguyen, L;Joesph, NI;Irengo, R;Cao, LY;Cumaran, M;Shi, Y;Lyu, S;Riley, L;Dunn, TW;Carmichael, ST;Segura, T; Clustered VEGF Nanoparticles in Microporous Annealed Particle (MAP) Hydrogel Accelerates Functional Recovery and Brain Tissue Repair after Stroke bioRxiv : the preprint server for biology 2025-02-05 [PMID: 39974959] (Human)
• T Yao, H Chen, R Wang, R Rivero, F Wang, L Kessels, SM Agten, TM Hackeng, TGAM Wolfs, D Fan, MB Baker, L Moroni Thiol-ene conjugation of VEGF peptide to electrospun scaffolds as potential application for angiogenesis Bioactive materials, 2022-06-08;20(0):306-317. 2022-06-08 [PMID: 35755423] (Human)
• L Koehler, G Ruiz-Gómez, K Balamuruga, S Rother, J Freyse, S Möller, M Schnabelra, S Köhling, S Djordjevic, D Scharnwebe, J Rademann, MT Pisabarro, V Hintze Dual Action of Sulfated Hyaluronan on Angiogenic Processes in Relation to Vascular Endothelial Growth Factor-A Sci Rep, 2019-12-02;9(1):18143. 2019-12-02 [PMID: 31792253] (Human)
• P Mésange, A Bouygues, N Ferrand, M Sabbah, AE Escargueil, A Savina, B Chibaudel, C Tournigand, T Andre, A de Gramont, AK Larsen Combinations of Bevacizumab and Erlotinib show activity in colorectal cancer independent of RAS status Clin. Cancer Res., 2018-02-28;0(0):. 2018-02-28 [PMID: 29490990] (Human)
• M Su, B Qin, F Liu, Y Chen, R Zhang Andrographolide enhanced 5-fluorouracil-induced antitumor effect in colorectal cancer via inhibition of c-MET pathway Drug Des Devel Ther, 2017-11-23;11(0):3333-3341. 2017-11-23 [PMID: 29200829] (Human)
• Raquel Costa Modulation of VEGF signaling in a mouse model of diabetes by xanthohumol and 8-prenylnaringenin: Unveiling the angiogenic paradox and metabolism interplay Mol Nutr Food Res, 2017-01-30;0(0):. 2017-01-30 [PMID: 27921359] (Human)
• Harris , Nicole C, Davydova , Natalia, Roufail , Sally, Paquet-Fifield , Sophie, Paavonen , Karri, Karnezis , Tara, Zhang , You-Fang, Sato , Teruhiko, Rothacker , Julie, Nice , Edouard, Stacker , Steven A, Achen , Marc G The propeptides of VEGF-D determine heparin binding, receptor heterodimerization, and effects on tumor biology. J Biol Chem, 2013-02-12;288(12):8176-86. 2013-02-12 [PMID: 23404505] (Human)
• Gavine PR, Mooney L, Kilgour E AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res., 2012-02-27;72(8):2045-56. 2012-02-27 [PMID: 22369928] (Human)
• Yamashita-Kashima Y, Fujimoto-Ouchi K, Yorozu K, Kurasawa M, Yanagisawa M, Yasuno H, Mori K Biomarkers for antitumor activity of bevacizumab in gastric cancer models. BMC Cancer, 2012-01-25;12(0):37. 2012-01-25 [PMID: 22273502] (Human)
• Martino MM, Hubbell JA The 12th-14th type III repeats of fibronectin function as a highly promiscuous growth factor-binding domain. FASEB J., 2010-07-29;24(12):4711-21. 2010-07-29 [PMID: 20671107] (Human)
• Xu Y, Yuan L, Mak J, Pardanaud L, Caunt M, Kasman I, Larrivee B, Del Toro R, Suchting S, Medvinsky A, Silva J, Yang J, Thomas JL, Koch AW, Alitalo K, Eichmann A, Bagri A Neuropilin-2 mediates VEGF-C-induced lymphatic sprouting together with VEGFR3. J. Cell Biol., 2010-01-11;188(1):115-30. 2010-01-11 [PMID: 20065093] (Human)
• Pan Q, Chathery Y, Wu Y, Rathore N, Tong RK, Peale F, Bagri A, Tessier-Lavigne M, Koch AW, Watts RJ Neuropilin-1 binds to VEGF121 and regulates endothelial cell migration and sprouting. J. Biol. Chem., 2007-06-16;282(33):24049-56. 2007-06-16 [PMID: 17575273] (Human)
• Favier B, Alam A, Barron P, Bonnin J, Laboudie P, Fons P, Mandron M, Herault JP, Neufeld G, Savi P, Herbert JM, Bono F Neuropilin-2 interacts with VEGFR-2 and VEGFR-3 and promotes human endothelial cell survival and migration. Blood, 2006-04-18;108(4):1243-50. 2006-04-18 [PMID: 16621967] (Human)

FAQs for VEGFR2/KDR/Flk-1 (DYC1766-2). (Showing 1 - 1 of 1 FAQs).

1. wondering what the difference is between your quantikine and duo set elisas?
   • Usually the duosets do not have the entire kit such as plates and buffers, whereas the other kits are complete.

Bioinformatics

• Gene Symbol: KDR